SEC Form 4 · accession 0000903423-18-000416

Liquidia Technologies Inc · LQDA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Other

Period of report

Jul 30, 2018

Accepted (ET)

Aug 1, 2018 · 6:32 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001330436

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F3,F2,F5	Jul 30, 2018	C	336,541	—	A	475,604	I	See explanation of responses
Common Stock^F4,F2,F5	Jul 30, 2018	C	118,570	—	A	475,604	I	See explanation of responses
Common Stock^F1,F2,F5	Jul 30, 2018	P	148,818	$11.00	A	624,422	I	See explanation of responses

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Series C-1 Preferred Stock^F5,F3	—	Jul 30, 2018	C	4,765,248	D	—	—	Common Stock	118,570	0	I
Series D Preferred Stock^F5,F4	—	Jul 30, 2018	C	344,853	D	—	—	Common Stock	336,541	0	I

F1On July 30, 2018, Glaxo Group Limited acquired 148,818 common shares of the Issuer ("Common Stock") at a price of $11.00 per share in connection with the Issuer's initial public offering.
F2Includes 20,493 shares of Common Stock issuable upon exercise of Series D Warrants. The Series D Warrants are currently exercisable, with an expiration date of December 31, 2026 and an exercise price of $0.01 per share. The exercise price may be paid in cash or through net share settlement at the option of the warrantholder.
F3The Series C-1 Preferred Stock converted automatically into Common Stock on an approximately 0.0706-for-one basis upon closing of the Issuer's initial public offering. The Series C-1 Preferred Stock had been convertible at any time at the holder's election and had no expiration date
F4The Series D Preferred Stock converted automatically into Common Stock on an approximately 0.0594 -for-one basis upon closing of the Issuer's initial public offering. The Series D Preferred Stock had been convertible at any time at the holder's election and had no expiration date.
F5The shares reported herein are held of record by Glaxo Group Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the "Reporting Person").